AB Corporate Bond ETF (NASDAQ:EYEG) Short Interest Update

AB Corporate Bond ETF (NASDAQ:EYEG) was the target of a large growth in short interest in the month of August. As of August 31st, there was short interest totaling 1,040 shares, a growth of 1,233.3% from the August 15th total of 78 shares. Based on an average trading volume of 668 shares, the days-to-cover ratio is presently 1.6 days. Currently, 0.0% of the company’s stock are sold short.

AB Corporate Bond ETF Stock Up 0.3%

Shares of NASDAQ EYEG traded up $0.09 during mid-day trading on Friday, reaching $34.10. 14 shares of the company were exchanged, compared to its average volume of 300. The company has a quick ratio of 3.07, a current ratio of 3.07 and a debt-to-equity ratio of 0.01. The stock has a market cap of $27.28 million, a price-to-earnings ratio of -20.30 and a beta of 0.18. AB Corporate Bond ETF has a 1 year low of $34.01 and a 1 year high of $36.63. The firm has a 50-day moving average of $34.64 and a 200 day moving average of $35.09.

AB Corporate Bond ETF Cuts Dividend

The company also recently declared a monthly dividend, which was paid on Friday, September 4th. Shareholders of record on Tuesday, September 1st were given a dividend of $0.1284 per share. This represents a c) annualized dividend and a dividend yield of 4.5%. The ex-dividend date of this dividend was Tuesday, September 1st. AB Corporate Bond ETF’s dividend payout ratio is presently -101.79%.

Institutional Inflows and Outflows

A hedge fund recently bought a new stake in AB Corporate Bond ETF stock. Kestra Advisory Services LLC purchased a new position in AB Corporate Bond ETF (NASDAQ:EYEG) during the 4th quarter, according to its most recent disclosure with the Securities and Exchange Commission (SEC). The fund purchased 951 shares of the specialty pharmaceutical company’s stock, valued at approximately $34,000. Kestra Advisory Services LLC owned about 0.13% of AB Corporate Bond ETF at the end of the most recent quarter. Institutional investors own 64.16% of the company’s stock.

AB Corporate Bond ETF Company Profile

EyeGate Pharmaceuticals, Inc is a clinical stage specialty pharmaceutical company, which engages in the development and commercialization of products for treating diseases and disorders of the eye. Its pipeline includes MoxiGel and Ocular Bandage Gel. The company was founded in 1998 and is headquartered in Waltham, MA.